“Bimekizumab Response Maintenance to 48 Weeks in Patients With Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s396, https://doi.org/10.25251/skin.8.supp.396.